• Home
  • About
  • UPCOMING WEBINARS & SEMINARS
  • Consultation
  • USP 61/62 FAQ
  • Contact

Barry A. Friedman, PhD LLC

FDA Regulatory Compliance for the Pharmaceutical, Biotechnology and Medical Device Arenas

TOP POSTINGS FROM THE BLOG OF BARRY A. FRIEDMAN, Ph.D., LLC — 2012

January 6, 2013 By Barry Friedman Leave a Comment

Often the question is asked "what were your top postings during the previous year.  This is an intriguing question since I don't know myself until I review the postings at the end of each year.  With an accumulation of over 70,000 views, it is of interest to determine what you, the viewers, deemed to be the most important. I have now sorted through the … [Read more...]

AMERIDOSE, LLC RECEIVES 15 OBSERVATIONS AS PART OF FORM FDA 483 (11/09/12)

November 14, 2012 By Barry Friedman Leave a Comment

SISTER COMPANY OF NECC RECEIVES TWENTY PAGE 483 CONTAINING SEVERAL REPEAT OBSERVATIONS COMMENT The FDA conducted an inspection of Ameridose, LLC, Westborough, MA from October 10 through November 9, 2012.  The investigation, involved fourteen Investigators and three microbiologists including one microbiologist from CDER.  A total of fifteen Observations including several … [Read more...]

NEW ENGLAND COMPOUNDING CENTER RECEIVES FDA 483 (10/26/12)

October 26, 2012 By Barry Friedman Leave a Comment

FDA INVESTIGATORS CONFIRM CONTAMINATION IN 50 OF 50 VIALS TESTED COMMENT The FDA issued its initial Form FDA 483 regarding the New England Compounding Center located in Framingham, MA.  The eight page, five item 483 describes the initial findings of their audit.  The Company now has 15 business days to submit its response to the FDA.  Of … [Read more...]

FDA’S CDER SUMMARIZES TOP TEN 483 OBSERVATIONS AT PDA/FDA MEETING IN BALTIMORE (9/12)

September 16, 2012 By Barry Friedman 2 Comments

COMMENT Each year CDER summarizes the number of significant Observations obtained from Form FDA 483s.  At this year's PDA/FDA meetings which were held in Baltimore, MD, the FDA presented the totals calendar year to date.  The Observations within the top ten usually do not change --- although their frequency may vary.  Where a specific section is indicated, the Title indicates … [Read more...]

MOST FREQUENTLY VIEWED POSTINGS — YEAR TO DATE FROM THE BLOG OF BARRY A FRIEDMAN, PhD

September 5, 2012 By Barry Friedman Leave a Comment

Periodically individuals have contacted me to learn of the "most frequently viewed postings" on my Blog.  On occasion, I ask myself the same question.  As a result I am posting the "top six" requested sites for your review.  You may find one or more of these postings of interest to you.  Each of these remains available and is easy … [Read more...]

« Previous Page
Next Page »
New Reader? Learn More

Connect With Me:

  • Email
  • Facebook
  • LinkedIn
  • RSS
  • Twitter

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Webinar Registration & Information

FREQUENTLY ASKED QUESTIONS:

FDA Form 483 Frequently Asked Questions

USP General Chapter

USP General Chapter 62, Part II

TOP OBSERVATIONS:

FDA’s CDER LISTING OF TOP NINETEEN OBSERVATIONS FOR 2014

FDA CDER Most Frequent Form FDA 483 Observations Fiscal Year 2012

CDER MOST FREQUENTLY CITED DRUG OBSERVATIONS – FISCAL YEAR 2010

Top Posts:

Top Posts for 2012

Top Posts for 2013

Top Posts Year To Date

Recent Posts

  • Upcoming Microbiological Webinars
  • Microbiological Webinars
  • Microbiological Webinars 2020 (Upcoming)
  • General Chapter (USP<60>) on B. cepacia Complex to Issue December 1, 2019
  • Les Produits Chimiques B.G.R., Inc. Receives FDA Warning Letter (07/24/2018) for Failure to Perform Laboratory Testing

Categories

follow us in feedly
  • Home
  • About
  • UPCOMING WEBINARS & SEMINARS
  • Consultation
  • USP 61/62 FAQ
  • Contact
  • Email
  • Facebook
  • LinkedIn
  • RSS
  • Twitter

Thank You For Visiting Barry A. Friedman, PhD LLC - 2015

Welcome To My Blog!
Please enter your name and email below to receive my newsletter.
Your information will *never* be shared or sold to a 3rd party.